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Acceleration in the Rate of CNS Remyelination in Lysolecithin-
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One important therapeutic goal during CNS injury from trauma
or demyelinating diseases such as multiple sclerosis is to de-
velop methods to promote remyelination. We tested the hy-
pothesis that spontaneous remyelination in the toxic nonim-
mune model of lysolecithin-induced demyelination can be
enhanced by manipulating the inflammatory response. In PBS-
treated SJL/J mice, the number of remyelinating axons per
square millimeter of lesion area increased significantly 3 and 5
weeks after lysolecithin injection in the spinal cord. How-
ever, methylprednisolone or a monoclonal antibody (mAb),
SCH94.03, developed for its ability to promote remyelination in
the Theiler’s virus murine model of demyelination, further in-
creased the number of remyelinating axons per lesion area at 3
weeks by a factor of 2.6 and 1.9, respectively, but did not
increase the ratio of myelin sheath thickness to axon diameter
or the number of cells incorporating tritiated thymidine in the
lesion. After 3 weeks, the number of remyelinating axons in the
methylprednisolone or mAb SCH94.03 treatment groups was
similar to the spontaneous remyelination in the 5 week PBS
control-treated group, indicating that these treatments pro-
moted remyelination by increasing its rate rather than its extent.
To address a mechanism for promoting remyelination, through
an effect on scavenger function, we assessed morphometrically
the number of macrophages in lesions after methylpred-
nisolone and mAb SCH94.03 treatment. Methylprednisolone
reduced the number of macrophages, but SCH94.03 did not,
although both enhanced remyelination. This study supports the
hypothesis that even in toxic nonprimary immune demyelina-
tion, manipulating the inflammatory response is a benefit in
myelin repair.
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Three general categories of experimental CNS demyelination can
be distinguished: (1) toxin-induced [cuprizone (Blakemore,
1973), ethidium bromide (Yajima and Suzuki, 1979), and lysolec-
ithin (Hall, 1972)]; (2) autoimmune-induced [experimental auto-
immune encephalomyelitis (EAE) (Raine and Traugott, 1985)];
and (3) virus-induced [corona virus (Herndon, 1977) and Thei-
ler’s murine encephalomyelitis virus (TMEV) (Rodriguez and
Lennon, 1990)]. Spontaneous CNS remyelination has been ob-
served in each of these models of demyelination in rodents. Some
CNS lesions of multiple sclerosis (MS) in humans are remyeli-
nated by oligodendrocytes (Prineas and Connell, 1979; Rodriguez
and Sheithauer, 1994) or Schwann cells (Ghatak et al., 1973),
although most lesions examined at autopsy show extensive demy-
elination and gliosis without myelin repair. In addition, demyeli-
nation and remyelination have been observed after acute spinal
cord compression (Gledhill et al., 1973). These observations sug-
gest that there is the potential for complete remyelination after
demyelination in spinal cord injury or multiple sclerosis, but there
are factors that prevent the full expression.
Two hypotheses have been proposed to explain the absence of
full remyelination in the human CNS (Rodriguez and Lindsley,
1992). The absence of significant spontaneous remyelination may
be attributable to either the presence of inhibitory elements
preventing myelin repair or the absence of cells or factors neces-
sary for new myelin synthesis. In the experimental model of
demyelination induced by TMEV, a natural enteric picornavirus
in mice, CNS remyelination can be promoted either by immuno-
suppression (Rodriguez and Lindsley, 1992) or by immunostimu-
lation by passive transfer of Igs such as CNS-specific antiserum
(Rodriguez et al., 1987), purified Ig (Rodriguez and Lennon,
1990), polyclonal mouse IgG (van Engelen et al., 1995), or a
monoclonal autoantibody (mAb) designated SCH94.03 (Miller et
al., 1994). The purpose of these experiments was to determine in
a toxic nonimmune model of demyelination whether corticoste-
roids suppress inhibitory elements for myelin repair, which would
allow for increasing the rate of spontaneous remyelination, and
whether stimulation of the humoral immune response by admin-
istration of polyclonal or monoclonal antibodies provides factors
for new myelin synthesis.
MATERIALS AND METHODS
Mice. Forty-six 12-week-old SJL/J (H-2 s) mice weighing 20–25 gm were
obtained from The Jackson Laboratory (Bar Harbor, ME). Mice were
housed in plastic cages, and food and water were provided ad libitum.
Handling of all animals conformed to the National Institute of Health
and Mayo Clinic institutional guidelines.
Surgery. Mice were anesthetized by intraperitoneal injection of sodium
pentabarbitol (0.08 mg/gm). Dorsal laminectomies were performed on
the upper thoracic region of the spinal cord. A 34 gauge needle attached
to a Hamilton syringe mounted on a stereotactic micromanipulator
was used to inject 1 ml of a 1% solution of lysolecithin (L-a-
lysophosphatidylcholine) (Sigma, St. Louis, MO) in sterile PBS, pH 7.4,
with Evan’s blue added as a marker. The needle was inserted into the
anterior or lateral part of the spinal cord, lysolecithin solution was
injected, and then the needle was slowly withdrawn. The wound was
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sutured in two layers, and mice were allowed to recover. The day of
lysolecithin injection was designated day 0.
Treatments. Mice were assigned randomly to groups (four to nine
animals per group) to receive the following treatments and were killed
on days 14 (n 5 6), 21 (n 5 34), and 35 (n 5 6) after lysolecithin injection.
All mice were 12 weeks of age to exclude the potential bias of age on
remyelination after demyelination (Gilson and Blakemore, 1993).
Methylprednisolone. Mice were treated with pulse doses of methylpred-
nisolone (Depo-Medrol, 80 mg/ml; Upjohn, Kalamazoo, MI) given by
intraperitoneal injections of 1 mg (;45 mg/kg) on days 0, 3, 7, 10, 14, and
17 to determine whether steroids would enhance remyelination. This
approach was used to test whether inhibition of the inflammatory re-
sponse would enhance myelin repair. This approach also simulated
treatments used in spinal cord injury (Bracken et al., 1990).
Polyclonal IgG. On days 7, 10, 14, and 17, mice were injected intra-
peritoneally twice daily with 0.5 mg of polyclonal IgG obtained from
multiple mouse donors (1 mg/ml in PBS from Sigma lot 033H8860). This
approach was identical to treatments used in other murine models in
which IgG had been shown to promote remyelination (van Engelen et al.,
1995). This approach also simulated the use of intravenous Ig (IvIg),
which has been shown to be beneficial in a subset of patients with
multiple sclerosis (Fazekas et al., 1997).
Anti-SCH Ig.Polyclonal Ig directed against spinal cord homogenate
(anti-SCH Ig) was shown to enhance remyelination in the TMEV model
of demyelination (Rodriguez et al. 1987, 1990). This was injected intra-
peritoneally (0.5 ml of 1.1 mg/ml solution) on days 7, 10, 14, and 17.
mAb SCH94.03 IgM-k. A monoclonal antibody developed in our lab-
oratory for its ability to promote remyelination in the TMEV model
(Miller and Rodriguez, 1995) was injected intraperitoneally (0.1 mg) on
days 7, 10, 14, and 17.
PBS. Control mice were given intraperitoneal injections of 0.5 ml of
PBS on days 7, 10, 14, and 17. Three groups of mice were killed on days
14, 21, and 35 after lysolecithin injection to address the normal temporal
profile of spontaneous remyelination in the lysolecithin model.
Histopathology. On days 14, 21, and 35, mice were killed for patholog-
ical analysis. After anesthesia with sodium pentobarbital, mice were
perfused with Trump’s fixative (phosphate-buffered 4% formaldehyde
containing 1% glutaraldehyde, pH 7.4). Spinal columns were removed
and allowed to post-fix for 1–3 d until spinal cords were removed. Six to
eight 1 mm coronal blocks were cut from the site marked by the Evan’s
blue marker. This assured that the entire lesion area was examined.
Serial blocks were kept in 24-well plates and washed with 0.1 M phos-
phate buffer. Blocks were secondarily fixed with osmium tetroxide and
dehydrated through a graded alcohol series, washed in propylene oxide
and embedded in Araldite (Polysciences, Warrington, PA). One-
micrometer sections were cut and stained with 4% paraphenylenedia-
mine. Selected areas were trimmed and prepared for electron micros-
copy. Ultrathin sections were placed on celloidin-coated 200-mesh grids,
stained with 4% uranyl acetate in 50% methanol and counterstained with
lead citrate. The grids were examined with a JEOL 1200 electron
microscope.
In vivo analysis of [ 3H]thymidine incorporation. To detect proliferating
cells, 40 animals were injected intraperitoneally with 100 mCi of [ 3H]thy-
midine (Amersham, Arlington Heights, IL) 48, 36, 24, and 12 hr before
killing on days 14 (n 5 5), 21 (n 5 29), and 35 (n 5 6). One-micrometer
sections of spinal cord from mice previously injected intraperitoneally
with [ 3H]thymidine were dipped in autoradiography emulsion (NTB2;
Eastman Kodak, Rochester, NY), sealed in black boxes, and exposed for
3 weeks at 4°C. Slides were developed in Kodak D19 developer, rinsed in
a distilled water stop bath, and fixed with Kodak fixer. Only lesion areas
that were at least 0.02 mm 2 in total area were studied morphometrically
to exclude the possibility that very small lesions would undergo more
rapid and extensive repair. Based on this assessment only five lesion
areas from 40 mice with lysolecithin-induced lesions were excluded from
the analysis.
Analysis of light and electron microscopic spinal cord section images. A
Zeiss (Oberkochen, Germany) interactive digital analysis system at-
tached to a Zeiss photomicroscope was used to measure the area (square
millimeters) of each lysolecithin lesion from every block. The lesion was
defined as the area that included axons that were completely and partially
demyelinated as well as completely and partially remyelinated (Fig. 1).
The lesion areas for each of the 35 mice killed at days 14, 21, and 35 were
summed to provide the total lesion area per mouse. This system was also
used to count the number of remyelinated axons in each lesion. Abnor-
mally thin myelin sheaths, relative to axonal diameter, were the criterion
for oligodendrocyte remyelination. Schwann cell remyelination was char-
acterized by thicker myelin sheaths, a one cell per axon relationship, and
a surrounding basement membrane. A cursor was used to mark each
remyelinated axon (oligodendrocyte or Schwann cell) with a cross, and
these were summed to determine the total number of remyelinated axons
per total lesion area.
Figure 1. Demonstration of the methodology for determining lesion area
measurements. A, Lysolecithin lesion from a PBS-treated control mouse 3
weeks after lysolecithin injection. B, Area in blue shows the normal white
matter surrounding lesion that was used to discriminate lesion. C, Area in
red demonstrates the area used in calculating the total lesion area.
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Lysolecithin lesion areas were also viewed on a JEOL 1200 electron
microscope. Areas of demyelination and oligodendrocyte-type remyeli-
nation were photographed. Photo negatives were incorporated into dig-
ital image files. These images were analyzed by the Zeiss digital analysis
system to determine the ratio of myelin thickness to axon diameter.
In vivo analysis of macrophage infiltration. A Zeiss interactive image
analysis system attached to a Zeiss photomicroscope was used to mea-
sure areas of phagocytic macrophage infiltrates in 41 lysolecithin lesion
areas from mice killed at days 14, 21, and 35 (Fig. 2). Macrophages were
readily identified in the lesions as cells with extensive myelin debris-
containing vacuoles. Because in certain areas macrophage infiltrates
were very dense and individual macrophages could not be distinguished,
cumulative areas of macrophage infiltrate were used to calculate the
number of macrophages per area of lesion. The total area of infiltration
was divided by the mean area of one macrophage (0.00127 mm 2) to yield
total macrophages. The data were expressed as number of macrophages
per square millimeter of lesion area.
Statistical analysis. Analyses were performed in a blinded manner on
coded slides. Pathological abnormalities were scored without knowledge
of treatment groups. Differences between treatment groups were ana-
lyzed using Kruskal–Wallis one-way ANOVA, and pairwise multiple
comparisons were done using Dunn’s method ( p , 0.05). Data that were
normally distributed were analyzed by one-way ANOVA, and pairwise
multiple comparisons were done by Dunnett’s method ( p , 0.05).
RESULTS
Demyelination and remyelination in PBS
control-treated SJL/J mice
Light and electron microscopy in the PBS-treated animals re-
vealed focal areas of demyelination, invading macrophages laden
with myelin debris, and thinly myelinated axons at 14, 21, and 35
days after lysolecithin injection (Fig. 3A). No differences in lesion
areas were found between the PBS-treated groups; the mean
area 6 SEM of lesion for these groups was 0.0709 6 0.015 mm2
(n 5 17). Few if any lymphocytes were identified in lesions, as
would be expected from toxin-induced demyelination. In previ-
ous pilot experiments we found that spontaneous oligodendro-
cyte remyelination, as detected by abnormally thin myelin sheaths
in relation to axon diameter, started ;1 week after lysolecithin
injection, as has been reported in the mouse (Jeffery and Blake-
more, 1995) and rat (Blakemore, 1976) previously. Most animals
also had some evidence of PNS-type remyelination, characterized
by the one-to-one relationship between CNS axons and Schwann
cells, and a basement membrane surrounding newly myelinated
Figure 2. Demonstration of the methodology for macrophage enumeration. A, Region of macrophage infiltration that does not allow for distinction of
individual cells. B, Region of macrophages from A discriminated to calculate total macrophage area. C, Region where individual macrophages can be
distinguished. D, Region discriminated from C used to calculate individual size of macrophages. Note examples of axons remyelinated by Schwann cells
(arrows).
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axons. Five weeks after lysolecithin injection the total number of
remyelinated axons per square millimeter of lesion area increased
significantly compared with the 2 and 3 week groups (Table 1).
The number of remyelinated axons per square millimeter in-
creased 2.6-fold from 2 to 3 weeks and 6.2-fold from 2 to 5 weeks
(Table 1). Myelin sheath thickness in axons remyelinated by
oligodendrocytes also increased spontaneously from 2 to 5 weeks
(Table 1, Fig. 4) but never reached the thickness observed in
normal axons.
Demyelination and remyelination in Ig- or
methylprednisolone-treated animals
At 3 weeks after lysolecithin injection, the total lysolecithin lesion
area was 0.098 6 0.01 mm2 (mean 6 SEM), based on the analysis
of the 23 mice shown in Table 2. There was no statistical differ-
ence in the lesion areas when comparing different treatment
groups. In contrast, there was a continuous increase in the num-
ber of remyelinating axons per square millimeter of lesion area
from the lowest in the PBS control group, increasing in the
Figure 3. Spinal cord sections from SJL/J
mice injected with lysolecithin and treated
with A, PBS control; B, methylprednisolone;
C, mAb 94.03; or D, polyclonal Ig directed
against spinal cord homogenate (SCH/Ig).
Treatment was begun on day 0 (methylpred-
nisolone) or day 7 (PBS control, mAb 94.03
or SCH/Ig) and continued until day 21 at
time of kill. Note focal area of demyelina-
tion with dense macrophage infiltration with
minimal remyelination in the mouse treated
with PBS control (A). In contrast, there is
oligodendrocyte remyelination, character-
ized by abnormally thin myelin sheath rela-
tive to axon diameter, and Schwann cell
remyelination in mice treated with methyl-
prednisolone (B), mAb SCH94.03 ( C ) or
SCH/Ig (D). The number of remyelinated
axons from sections such as these are shown
in Tables 1 and 2 (3 750).
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polyclonal IgG, anti-SCH Ig, and mAb SCH94.03 to the highest in
the methylprednisone group (Table 2).
Polyclonal IgG and anti-SCH Ig did not statistically improve
remyelination, whereas mAb SCH94.03 and methylprednisolone
treatment statistically increased the number of remyelinated ax-
ons per square millimeter of lesion area at the 3 week time point
by a factor of 1.9 and 2.6, respectively (Table 2, Fig. 3). After 3
weeks the total number of remyelinated axons per square milli-
meter in the mAb SCH94.03 or methylprednisolone treatment
groups (Table 2) was comparable with the spontaneous remyeli-
nation observed in the 5 week PBS control group (Table 1). The
various treatments did not increase the ratio of myelin sheath
thickness to axon diameter in fibers undergoing oligodendrocyte-
type remyelination (Table 2).
In vivo analysis of [3H]thymidine incorporation
Although the number of cells incorporating [3H]thymidine de-
creased from 2 to 5 weeks after lysolecithin injection, no statisti-
cal differences were observed in the PBS control groups (Fig. 5).
Furthermore, the number of cells incorporating [3H]thymidine in
the various treatments did not differ statistically from the 3 week
PBS control group (Fig. 5). The greatest number of proliferating
cells was observed in mice receiving poly-IgG, but this was not
statistically significant (Fig. 5). Although corticosteroids are po-
tent antiproliferative agents for macrophages and other inflam-
matory cells, cells incorporating [3H]thymidine (presumed glial
cells) were observed in mice receiving this treatment. Some
[ 3H]thymidine-positive cells were identified as inflammatory (i.e.,
surrounding blood vessels or infiltrating the spinal cord paren-
chyma from the meninges). A few proliferating Schwann cells
were observed near the root entry zone associated with PNS-type
remyelination. Many of the [3H]thymidine-positive noninflam-
matory cells were presumptive glia near areas of oligodendrocyte
remyelination. As described previously (Rodriguez and Lindsley,
1992), these cells had large nuclei without a definite nucleolus, a
non-electron-dense cytoplasm, and no distinct glial fibrils and
were usually at a distance from dense inflammatory infiltrates.
In vivo analysis of macrophage infiltration
One potential mechanism for enhancing remyelination is by ef-
fecting the recruitment or function of scavenger macrophages in
the lesion. Removal of myelin debris from the lesion could then
allow progenitor glia to proliferate and differentiate to initiate
myelination. We first assessed the number of macrophages in
lysolecithin lesions induced at 2, 3, and 5 weeks before killing.
The number of macrophages/mm2 of lesion for PBS-treated mice
injected with lysolecithin was 731 6 79 (n 5 6) at 2 weeks
(mean 6 SEM), 1044 6 185 at 3 weeks, and 643 6 69 (n 5 6) at
5 weeks. Although the number of macrophages appeared to peak
at 3 weeks, there was no statistical difference in the data. To test
Table 1. Spontaneous remyelination in PBS-treated SJL/J mice after
lysolecithin injection in the spinal cord
Time after lyso-
lecithin injection
Remyelinated axonsa,b
(No./mm2 lesion)
G ratio: myelin sheathc,d,e
thickness/axon diameter
(%)
2 weeks 721 6 117 (6) 6.7 6 0.6 (33)
3 weeks 1875 6 323 (5) 9.6 6 0.4 (92)
5 weeks 4312 6 1282 (6) 12.8 6 0.7 (93)
aNumber in parentheses shows the number of mice examined; data expressed as
mean 6 SEM.
bBy ANOVA on Ranks, the number of remyelinated axons was increased signifi-
cantly from 2 weeks to 5 weeks ( p , 0.05).
cNumber in parentheses indicates the number of axons remyelinated by oligoden-
drocytes studied by electron microscopy; data expressed as mean 6 SEM.
dBy ANOVA on ranks, the ratio of myelin sheath thickness to axon diameter was
increased statistically from 2 weeks to 5 weeks ( p , 0.0001). All pairwise multiple
comparison procedures (Dunn’s method) revealed significant differences ( p , 0.05)
when comparing G ratios between 2 week, 3 week, and 5 week groups.
eNormal myelinated axons (n 5 127) produced a G-ratio of 18.1 6 0.4.
Figure 4. Relative myelin sheath thickness as a function of axon diam-
eter in axons remyelinated by oligodendrocytes at 2, 3 or 5 weeks in
PBS-treated SJL/J mice injected with lysolecithin.
Table 2. Effects of corticosteroids and Ig treatment on remyelination 3
weeks after lysolecithin-induced demyelination in the spinal cord
Treatment
Lesion areac,d
(mm2)
Remyelinated
axonsc,e (No./
mm2 lesion)
G ratio: mye-
lin sheathf,g
thickness/axon
diameter (%)
PBS controla 0.131 6 0.01 (5) 1875 6 323 (5) 9.6 6 0.4 (92)
Polyclonal IgGa 0.127 6 0.03 (4) 2668 6 506 (4) 9.3 6 0.6 (74)
Anti-SCH Iga 0.128 6 0.02 (5) 3411 6 593 (5) 8.0 6 0.5 (69)
MAb SCH 94.03a 0.079 6 0.02 (4) 3983 6 627 (4) 8.2 6 0.5 (76)
Methylprednisoloneb 0.087 6 0.03 (5) 4561 6 1085 (5) 8.7 6 0.5 (87)
aTreatment given on days 7, 10, 14 and 17 following lysolecithin.
bTreatment given on days 0, 3, 7, 10, 14 and 17 following lysolecithin.
cNumber in parentheses indicates the number of mice examined; data expressed as
mean 6 SEM.
dBy ANOVA the size of lesion area was not significantly different between groups
( p . 0.05).
eBy ANOVA the number of remyelinated axons was significantly different between
the groups ( p , 0.05). Student’s t test showed significant differences between PBS
control versus mAb SCH94.03 ( p 5 0.02) and PBS control versus methylpred-
nisolone ( p 5 0.02).
fNumber in parentheses indicates the number of axons remyelinated by oligoden-
drocytes studied by electron microscopy; data expressed as mean 6 SEM.
gNo significant differences were observed in the G-ratio by ANOVA.
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the hypothesis that a change in the macrophage infiltrate would
correlate with enhanced remyelination, we analyzed the number
of macrophages per square millimeter in treatment groups at the
3 week time point. There was a statistically significant difference
between the PBS-treated group and the methylprednisolone
group by Dunnett’s multiple comparison procedure (Fig. 6). Of
interest, however, no decrease in the number of macrophages per
lesion area was observed in the 94.03-treated group, which statis-
tically enhanced remyelination, or in the anti-SCH Ig and poly-
IgG groups, which did not significantly enhance remyelination.
This result indicates that the mechanism of enhanced remyelina-
tion between methylprednisolone and 94.03 may be fundamen-
tally different.
DISCUSSION
This study demonstrated that spontaneous remyelination in a
toxic–traumatic model of demyelination is a normal physiological
response that can be promoted either by treatment with cortico-
steroids or by immunostimulation using mAb SCH94.03. These
findings are comparable with experiments published previously in
an immune-mediated virus model of demyelination, in which
immunosuppression (Rodriguez and Lindsley, 1992) or mAb
SCH94.03 (Miller et al., 1994) was able to promote CNS-type
remyelination. Although there may be differences in the role of
the inflammatory response in the genesis of toxic–traumatic
versus virus-induced demyelination, the present study showed
that a beneficial therapeutic effect by agents that potentially
influence inflammation is not restricted to immune-mediated
demyelination.
Theoretically a beneficial therapeutic effect could be caused
either by decreasing demyelination or by increasing remyelina-
tion. Corticosteroid treatment could have been beneficial by in-
hibiting directly lysolecithin-induced demyelination, as reported
by Triarhou and Herndon (1986). Lysolecithin injection causes
primary myelin breakdown by increasing phospholipase A2 activ-
ity contained in activated macrophages (Trotter and Smith, 1986),
which degrades membrane phosphatidylcholine into lysolecithin
(Weltzien, 1979). Because corticosteroids inhibit phospholipase
A2 (Crompton et al., 1988), they could counteract directly the
demyelinating effect of lysolecithin on phospholipase A2. How-
ever, we found that corticosteroid administered within 0.5–1 hr
after lysolecithin injection did not significantly decrease the lesion
area. This is in contrast with the report of Triarhou and Herndon
Figure 5. Number of proliferating cells per mm 2 of lesion in PBS-treated groups and treatment groups at 3 weeks after lysolecithin injection (data
expressed as proliferating cells per square millimeter of lesion 1 SEM). n, Number of mice studied.
Figure 6. Number of macrophages per lesion area in treatment
groups (data expressed as macrophages per square millimeter of
lesion 1 SEM). n, Number of mice studied. Data marked by *
denote statistical significance by Dunnett’s multiple comparison
procedure with the PBS-treated group serving as the control.
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(1986) on dexamethasone acetate administration in rats, but the
latter study did not specify the interval between lysolecithin
injection and corticosteroid administration. In patients with acute
spinal cord injury, treatment with methylprednisolone (as a bolus
of 30 mg/kg followed by 5.4 mg z kg21 z hr21 for 23 hr) improves
neurological recovery when the medication is given within the
first 8 hr (Bracken et al., 1990), possibly by preventing the break-
down of membranes (Braughler and Hall, 1983). In our lysoleci-
thin experiments, methylprednisolone was administered for 17 d
instead of 23 hr as in the human trial (Bracken et al., 1990). Our
results raise the possibility that the therapeutic effect of methyl-
prednisolone in toxic or traumatic spinal cord injury may in part
be the result of enhanced remyelination.
Two potential mechanisms exist by which treatment may pro-
mote spontaneous remyelination (Miller et al., 1994). First, some
pathogenic component preventing full remyelination may be in-
hibited. If the outcome of the demyelinating process is based on
a balance between tissue destruction and repair, inhibiting those
components that prevent healing would allow a physiological
repair response to predominate. Thus, corticosteroids may have
promoted spontaneous CNS remyelination by their anti-
inflammatory effects; i.e., perturbation of leukocyte trafficking,
lytic action on lymphocytes, and inhibition of T-lymphocyte ac-
tivation (Cupps and Fauci, 1982), or by interfering with locally
secreted cytokines and lymphokines of interest. In these experi-
ments the number of macrophages infiltrating the lesion at 3
weeks was significantly reduced in the methylprednisolone-
treated group, which is consistent with the first hypothesis. Of
interest, methylprednisolone has also been shown to inhibit in-
flammatory processes in experimental spinal cord lesions in the
rat (Bartholdi and Schwab, 1995). Corticosteroids also directly
effect lymphokine production, especially interleukin 1 (Lew et al.,
1988), and interleukin-2 (IL-2) (Arya et al., 1984; Boumpas et al.,
1991). IL-2 has been shown to stimulate (Benveniste and Merrill,
1986) or inhibit (Knobler et al., 1988) differentiation of oligoden-
drocytes depending on the microenvironment. Therefore, corti-
costeroids may have promoted remyelination in vivo by inhibiting
a pathogenic component from the microenvironment, thereby
allowing the normal physiological response to predominate. Of
interest, SCH94.03 has also been shown in vivo to have local
immunosuppressive properties because treatment with the anti-
body successfully prevents further relapses of experimental au-
toimmune encephalomyelitis (Miller et al., 1997) and suppresses
CNS inflammation after Theiler’s virus-induced demyelination
(Miller et al., 1996). This effect appears to be primarily a T-cell
rather than macrophage phenomenon, which may explain the
dissociation of mechanism of action between methylprednisolone
and SCH94.03, as supported by the results (Fig. 6).
Second, treatment may have promoted remyelination by ac-
tively stimulating myelination in vivo. Corticosteroids, either ex-
ogenously administered or endogenously synthesized by glial
cells (Jung-Testas et al., 1989), have been shown to promote gene
transcription (Gronemeyer, 1992), in particular on rat glial cul-
tures (Kumar et al., 1989). Glucocorticoids are also co-mitogens
for Schwann cells (Neuberger et al., 1994). The mAb SCH94.03
may also have had a direct stimulatory effect on oligodendrocytes
(Asakura et al., 1996a). mAb SCH94.03 labels a surface antigen
on a subpopulation of mature murine oligodendrocytes raising
the possibility that it promotes remyelination by binding directly
to a surface receptor (Asakura et al., 1996). The mAb SCH94.03
also localizes to the lesions after in vivo administration and binds
to glia, myelin, macrophages, and some axons (Hunter et al.,
1997). Other antibodies that directly stimulate oligodendrocyte
differentiation include the O4 mAb (Bansal et al., 1988) and an
mAb against a reovirus receptor expressed by oligodendrocytes
(Cohen et al., 1991). Therefore, methylprednisone and mAb
SCH94.03 may have promoted remyelination by stimulating di-
rectly remyelination by oligodendrocytes.
At the inception of these experiments we predicted that those
therapeutic strategies that would have enhanced remyelination
also would have resulted in increased [H 3]thymidine uptake in
the lesion. This was a logical conclusion based on elegant previous
studies demonstrating that proliferation of progenitor glial cells is
necessary before remyelination (Ludwin, 1979; Armstrong et al.,
1990; Prayoonwiwat and Rodriguez, 1993; Carrol and Jennings,
1994). However, no statistical differences were observed in the
number of proliferating cells in the lesions at 3 weeks after the
various strategies to promote remyelination. We cannot exclude
the possibility that a change in the number of proliferating cells
between the various groups would have been seen if examined
before 3 weeks. Although we did not do double-labeling experi-
ments to identify the phenotype of these cells, previous experi-
ments in other models of demyelination indicate that the majority
of the proliferating cells are glial (Armstrong et al., 1990;
Prayoonwiwat and Rodriguez, 1993). The results of our experi-
ments indicate that the stimuli for inducing proliferation, a likely
prerequisite for remyelination, are independent of the treatment
paradigms we used. The result suggests that once these cells have
proliferated, the approach used here allows for more rapid and
efficient myelin synthesis.
Treatment with mAb SCH94.03 increased statistically the num-
ber of remyelinated axons per lysolecithin lesion area at 3 weeks,
whereas polyclonal Ig and anti-SCH Ig did not enhance remyeli-
nation using the same dose and duration of treatment as in our
TMEV studies (Rodriguez and Lennon, 1990; van Engelen et al.,
1995). These results are intriguing and clearly indicate that with
increasing specificity of the Ig preparation (from polyclonal Ig,
polyclonal anti-SCH Ig, to mAb SCH94.03) remyelination also
increased (Table 2). This raises the possibility that remyelination-
promoting antibodies may be present in normal serum but at a
low concentration. The mAb SCH94.03 has the phenotype of
naturally occurring or physiological autoantibodies, which are
found in the serum of normal humans and mice, are polyreactive
with a wide range of antigens (Asakura et al., 1996b), and are
encoded by germ line Ig light- and heavy-chain genes without
definitive somatic mutations (Miller et al., 1995). The enhance-
ment of remyelination in the lysolecithin model implies that
certain natural autoantibodies may participate in a beneficial
physiological response to CNS injury, even in nonimmune
demyelination.
REFERENCES
Armstrong R, Friedrich Jr VL, Holmes KV, Dubois-Dalcq M (1990) In
vitro analysis of the oligodendrocyte lineage in mice during demyeli-
nation and remyelination. J Cell Biol 111:1183–1195.
Arya SK, Wong-Staal F, Gallo RC (1984) Dexamethasone-mediated in-
hibition of human T-cell growth factor and gamma-interferon messen-
ger RNA. J Immunol 133:273–276.
Asakura K, Miller DJ, Murray K, Bansal R, Pfeiffer SE, Rodriguez M
(1996a) Monoclonal autoantibody SCH94.03 which promotes CNS re-
myelination recognizes an antigen on the surface of oligodendrocytes.
J Neurosci Res 43:273–281.
Asakura K, Pogulis RJ, Pease LR, Rodriguez M (1996b) A monoclonal
autoantibody which promotes central nervous system remyelination is
highly polyreactive to multiple known and novel antigens. J Neuroim-
munol 65:11–19.
2504 J. Neurosci., April 1, 1998, 18(7):2498–2505 Pavelko et al. • Promotion of CNS Remyelination
Bansal R, Gard AL, Pfeiffer SE (1988) Stimulation of oligodendrocyte
differentiation in culture by growth in the presence of a monoclonal
antibody to sulfated glycolipid. J Neurosci Res 21:260–267.
Bartholdi D, Schwab ME (1995) Methylprednisolone inhibits early in-
flammatory processes but not ischemic cell death after experimental
spinal cord lesion in rat. Brain Res 672:177–186.
Benveniste EN, Merrill JE (1986) Stimulation of oligodendroglial pro-
liferation and maturation by interleukin-2. Nature 321:610–613.
Blakemore WF (1973) Demyelination in the superior cerebellar pedun-
cle in the mouse induced by Cuprizone. J Neurol Sci 20:63–72.
Blakemore WF (1976) Invasion of Schwann cells into the spinal cord of
the rat following local injections of lysolecithin. Neuropath Appl Neu-
robiol 2:21–39.
Boumpas DT, Anastassiou ED, Older SA, Tsokos GC, Nelson DL, Balow
JE (1991) Dexamethasone inhibits human interleukin 2 but not inter-
leukin 2 receptor gene expression in vitro at the level of nuclear
transcription. J Clin Invest 87:1739–1747.
Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin
DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon J, Marshall
LF, Perot Jr PL, Piepmeir J, Sonntag VKH, Wagner FC, Wilberger JE,
Winn HR. (1990) A randomized controlled trial of methylpred-
nisolone or naloxone in the treatment of acute spinal-cord injury.
N Engl J Med 322:1405–1411.
Braughler JM, Hall ED (1983) Correlation of methylprednisolone levels
in cat spinal cord with its effects on (Na 1 K 1)-ATPase, lipid peroxi-
dation, and alpha motor neuron function. J Neurosurg 56:838–844.
Carrol WM, Jennings AR (1994) Early recruitment of oligodendrocyte
precursors in CNS demyelination. Brain 117:563–578.
Cohen JA, Williams WV, Geller HM, Greene MI (1991) Anti-reovirus
receptor antibody accelerates expression of the optic nerve oligoden-
drocyte developmental program. Proc Natl Acad Sci USA
88:1266–1270.
Crompton MR, Moss SE, Crumpton MJ (1988) Diversity in the lipocor-
tin/calpactin family. Cell 55:1–3.
Cupps TR, Fauci AS (1982) Corticosteroid mediated immunoregulation
in man. Immunol Rev 65:133–155.
Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B
(1997) Randomised placebo-controlled trial of monthly intravenous
immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lan-
cet 349:589–593.
Ghatak NR, Hirano A, Doron Y, Zimmerman HM (1973) Remyelina-
tion in multiple sclerosis with peripheral type myelin. Arch Neurol
29:262–267.
Gilson J, Blakemore WF (1993) Failure of remyelination in areas of
demyelination produced in the spinal cord of old rats. Neuropathol
Appl Neurobiol 19:173–181.
Gledhill RF, Harrison BM, McDonald WI (1973) Demyelination and
remyelination after acute spinal cord compression. Exp Neurol
38:472–487.
Gronemeyer H (1992) Control of transcription activation by steroid hor-
mone receptors. FASEB J 6:2524–2529.
Hall SM (1972) The effect of injections of lysophosphatidyl choline into
white matter of the adult mouse spinal cord. J Cell Sci 13:257–277.
Herndon RM, Price DP, Weiner LP (1977) Regeneration of oligoden-
droglia during recovery from demyelinating disease. Science 195:
693–694.
Hunter SF, Miller DJ, Rodriguez M (1997) Monoclonal remyelination-
promoting natural autoantibody sch 94.03 –pharmacokinetics and in
vivo targets within demyelinated spinal cord in a mouse model of
multiple sclerosis. J Neurol Sci 150:103–113.
Jeffery ND, Blakemore WF (1995) Remyelination of mouse spinal cord
axons demyelinated by local injection of lysolecithin. J Neurocytol
24:775–781.
Jung-Testas I, Hu ZY, Baulieu EE, Robel P (1989) Neurosteroids: bio-
synthesis of pregnenolone and progesterone in primary cultures of rat
glial cells. Endocrinology 125:2083–2091.
Knobler RL, Saneto RP, Altman A, Johnson HM, de Vellis J (1988)
Interleukin-2 blocks oligodendrocyte progenitor proliferation. Ann NY
Acad Sci 540:324–426.
Kumar S, Cole R, Chiappelli F, De Vellis J (1989) Differential regula-
tion oligodendrocyte markers by glucocorticoids: post transcriptional
regulation of both proteolipid protein and myelin basic protein and
transcriptional regulation of glycerol phosphate dehydrogenase. Proc
Natl Acad Sci USA 86:6807–6811.
Lew W, Oppenheim JJ, Matsushima K (1988) Analysis of the suppres-
sion of IL-1 alpha and IL-1 beta production in human peripheral blood
mononuclear adherent cells by a glucocorticoid hormone. J Immunol
140:1895–1902.
Ludwin SK (1979) An autoradiographic study of cellular proliferation in
remyelination of the central nervous system. Am J Pathol 95:683–696.
Miller DJ, Rodriguez M (1995) A monoclonal antibody that promotes
central nervous system remyelination in a model of multiple sclerosis is
a natural autoantibody encoded by germline immunoglobulin genes.
J Immunol 154:2640–2649.
Miller DJ, Sanborn KS, Katzmann JA, Rodriguez M (1994) Monoclonal
autoantibodies promote central nervous system repair in an animal
model of multiple sclerosis. J Neurosci 14:6230–6238.
Miller DJ, Njenga MK, Murray PD, Leibowitz J, Rodriguez M (1996) A
monoclonal natural autoantibody that promotes remyelination sup-
presses central nervous system inflammation and increases virus ex-
pression after Theiler’s virus-induced demyelination. Int Immunol
8:131–141.
Miller DJ, Bright JJ, Sriram S, Rodriguez M (1997) Successful treat-
ment of established relapsing experimental autoimmune encephalomy-
elitis in mice with a monoclonal natural autoantibody. J Neuroimmunol
75:204–209.
Neuberger TJ, Kalimi O, Regelson W, Kalimi M, De Vries GH (1994)
Glucocorticoids enhance the potency of Schwann cell mitogens. J Neu-
rosci Res 38:300–313.
Prayoonwiwat N, Rodriguez M (1993) The potential for oligodendro-
cyte proliferation during demyelinating disease. J Neuropath Exp
Neurol 52:55–63.
Prineas JW, Connell F (1979) Remyelination in multiple sclerosis. Ann
Neurol 5:22–31.
Raine CS, Traugott U (1985) Remyelination in chronic relapsing exper-
imental allergic encephalomyelitis and multiple sclerosis. In: The pa-
thology of myelinated axon (Adachi M, Hirano A, Aronson SM eds),
pp 229–275. New York: Igaku-Shoin.
Rodriguez M, Lennon VA (1990) Immunoglobulins promote remyelina-
tion in the central nervous system. Ann Neurol 27:12–17.
Rodriguez M, Lindsley MD (1992) Immunosuppression promotes CNS
remyelination in chronic virus-induced demyelinating disease. Neurol-
ogy 42:348–357.
Rodriguez M, Sheithauer B (1994) Ultrastructure of multiple sclerosis.
Ultrastruct Pathol 18:3–13.
Rodriguez M, Lennon VA, Benveniste EN, Merrill JE (1987) Remyeli-
nation by oligodendrocytes stimulated by antiserum to spinal cord.
J Neuropathol Exp Neurol 46:84–95.
Triarhou LC, Herndon RM (1986) The effect of dexamethasone on
L-alphalysolphosphatidyl choline (lysolecithin)-induced demyelination.
Arch Neurol 43:121–125.
Trotter J, Smith ME (1986) The role of phospholipases from inflamma-
tory macrophages in demyelination. Neurochem Res 11:349–361.
Van Engelen BGM, Miller DJ, Pavelko KD, Hommes OR, Rodriguez M
(1995) Promotion of remyelination by polyclonal immunoglobulin in
Theiler’s virus-induced demyelination and in multiple sclerosis. J Neu-
rol Neurosurg Psychiatry 57:65–68.
Weltzien HU (1979) Cytolytic and membrane-perturbing properties of
lysophosphatidylcholine. Biochim Biophys Acta 559:259–287.
Yajima K, Suzuki K (1979) Demyelination and remyelination in the rat
central nervous system following ethidium bromide injection. Lab In-
vest 41:385–392.
Pavelko et al. • Promotion of CNS Remyelination J. Neurosci., April 1, 1998, 18(7):2498–2505 2505
